2016
DOI: 10.1159/000441250
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata

Abstract: Background: In severe alopecia areata (AA), spontaneous recovery is unlikely, and treatment is not standardized. Objective: To evaluate the efficacy and safety of methotrexate (MTX) used alone or combined with low- to moderate-dose oral corticosteroids (OC) for treating severe AA (totalis, universalis and severe multifocal). Methods: Retrospective monocentric study of all consecutive patients receiving this treatment between 2006 and 2012. Efficacy was defined as achieving a total regrowth of terminal hair. Re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
20
0
2

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 29 publications
(22 citation statements)
references
References 30 publications
0
20
0
2
Order By: Relevance
“…A response to methotrexate (an immune suppressant) has been reported in several case series 162164 . However, many patients also received systemic corticosteroids, and owing to the lack of controls, this makes it difficult to assess the magnitude of any benefit.…”
Section: Mechanisms/pathophysiologymentioning
confidence: 99%
“…A response to methotrexate (an immune suppressant) has been reported in several case series 162164 . However, many patients also received systemic corticosteroids, and owing to the lack of controls, this makes it difficult to assess the magnitude of any benefit.…”
Section: Mechanisms/pathophysiologymentioning
confidence: 99%
“…Focusing on the pediatric patients, three out of four achieved a complete regrowth, but a later relapse was observed in two of them. [10]…”
Section: Discussionmentioning
confidence: 99%
“…[2] However, the need for a maintenance treatment with MTX after achieving a successful hair growth rate has also been proposed. [610] If there is no response after 6–9 months, MTX should be stopped. [2]…”
Section: Discussionmentioning
confidence: 99%
“…Albeit rare, MIP can occasionally evolve to pulmonary fibrosis following acute as well as chronic therapy, with subsequent increase in mortality rate (Ameen, Taylor, Williams, Wells, & Barkert, 2001;Anuset, Perceau, Bernard, & Reguiai, 2016;Mazokopakis et al, 2004). MIP has no apparent correlation with age, sex, total dosage of the drug, or duration of treatment.…”
Section: Com M En Tmentioning
confidence: 99%